COVID-19 case fatality rate and tuberculosis in a metropolitan setting.

Daniel Rojas-Bolivar, Claudio Intimayta-Escalante, Ariana Cardenas-Jara, Roman Jandarov, Moises A Huaman
Author Information
  1. Daniel Rojas-Bolivar: Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales (CITBM), Callao, Peru. ORCID
  2. Claudio Intimayta-Escalante: Sociedad Científica de San Fernando (SCSF), Lima, Peru. ORCID
  3. Ariana Cardenas-Jara: Facultad de Medicina, Universidad Nacional Mayor de San Marcos (UNMSM), Lima, Peru. ORCID
  4. Roman Jandarov: Department of Biostatistics and Bioinformatics, University of Cincinnati, Cincinnati, Ohio. ORCID
  5. Moises A Huaman: Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA. ORCID

Abstract

In this study, we aimed to assess the relationship between tuberculosis case rate and COVID-19 case fatality rate (CFR) among districts within a tuberculosis-endemic metropolitan area. We analyzed data from 43 districts in Lima, Peru. We used districts as the units of observation. Linear regressions were used to investigate the relationship between COVID-19 CFRs and tuberculosis case rates. The mean COVID-19 CFR in each district for reporting Weeks 5-32 was used as the dependent variable. Independent variable was the mean rate of confirmed pulmonary tuberculosis cases for 2017-2019 period. Analyses were adjusted by population density, socioeconomic status, crowded housing, health facility density, and case rates of hypertension, diabetes mellitus, and HIV infection. The mean COVID-19 CFR in Lima was 4.0% ± 1.1%. The mean tuberculosis rate was 16.0 cases per 10,000 inhabitants. In multivariate analysis, tuberculosis case rate was associated with COVID-19 CFR (β = 1.26; 95% confidence interval: 0.24-2.28; p = .02), after adjusting for potential confounders. We found that Lima districts with a higher burden of tuberculosis exhibited higher COVID-19 CFRs, independent of socioeconomic, and morbidity variables.

Keywords

References

  1. J Med Virol. 2021 Jan;93(1):194-196 [PMID: 32687228]
  2. Indian J Tuberc. 2020 Dec;67(4S):S155-S162 [PMID: 33308662]
  3. Commun Biol. 2021 Mar 5;4(1):290 [PMID: 33674719]
  4. Eur Respir J. 2020 Jul 9;56(1): [PMID: 32457198]
  5. Lancet Glob Health. 2020 Sep;8(9):e1132-e1141 [PMID: 32673577]
  6. Infect Dis (Lond). 2020 Nov - Dec;52(12):902-907 [PMID: 32808838]
  7. BMC Infect Dis. 2020 Oct 9;20(1):744 [PMID: 33036570]
  8. Clin Microbiol Infect. 2021 Feb;27(2):293-294 [PMID: 32822881]
  9. J Med Virol. 2021 May;93(5):3273-3276 [PMID: 33570198]
  10. Eur Respir J. 2020 Jul 9;56(1): [PMID: 32444399]
  11. Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015 [PMID: 32860699]
  12. Pulmonology. 2020 Jul - Aug;26(4):233-240 [PMID: 32411943]

MeSH Term

COVID-19
Cities
Humans
Linear Models
Peru
Tuberculosis, Pulmonary

Word Cloud

Created with Highcharts 10.0.0tuberculosisCOVID-19caserateCFRdistrictsmeanfatalityLimausedrelationshipmetropolitanPeruCFRsratesvariablecasesdensitysocioeconomic10higherstudyaimedassessamongwithintuberculosis-endemicareaanalyzeddata43unitsobservationLinearregressionsinvestigatedistrictreportingWeeks5-32dependentIndependentconfirmedpulmonary2017-2019periodAnalysesadjustedpopulationstatuscrowdedhousinghealthfacilityhypertensiondiabetesmellitusHIVinfection40%±1%16per10000inhabitantsmultivariateanalysisassociatedβ=2695%confidenceinterval:24-228p = 02adjustingpotentialconfoundersfoundburdenexhibitedindependentmorbidityvariablessetting

Similar Articles

Cited By